Drugs / MDCO-216
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02678923 | Dec 2015 → Oct 2016 | acute coronary syndrome | The Medicines Company | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDCO-216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02678923 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Apo A-I Milano (rApoA-IM)” NCT02678923 ↗ |
| Route | Intravenous | “20 mg/kg of MDCO-216 administered intravenously (IV)” NCT02678923 ↗ |